

**Balance Sheet**  
**APTIL PHARMA LTD**

	Notes	As at		Amt. in lacs	
		31-Mar-2016 GBP	31-Mar-2016 INR	31-Mar-2015 GBP	31-Mar-2015 INR
<b>EQUITY AND LIABILITIES</b>					
<b>Shareholder's funds</b>					
Share capital	1	-	-	-	-
Reserves and surplus	2	(9.26)	(880.52)	(8.31)	(768.33)
		<u>(9.26)</u>	<u>(880.52)</u>	<u>(8.31)</u>	<u>(768.33)</u>
<b>Current liabilities</b>					
Short term borrowings	3	47.10	4,478.65	42.10	3,892.53
Trade payables		5.85	556.27	8.04	743.36
Other current liabilities	5	0.46	43.74	0.58	53.63
		<u>53.41</u>	<u>5,078.66</u>	<u>50.72</u>	<u>4,689.52</u>
<b>TOTAL</b>		<u><u>44.15</u></u>	<u><u>4,198.14</u></u>	<u><u>42.41</u></u>	<u><u>3,921.19</u></u>
<b>ASSETS</b>					
<b>NON CURRENT ASSETS</b>					
Fixed Assets					
Intangible Assets	6	0.41	38.99	-	-
Intangible assets under development		41.20	3,917.63	41.24	3,813.01
Deferred Tax Asset (Net)	4	2.31	219.65	-	-
		<u>43.92</u>	<u>4,176.27</u>	<u>41.24</u>	<u>3,813.01</u>
<b>CURRENT ASSETS</b>					
Cash and cash equivalents	8	0.23	21.87	1.06	98.01
Other current assets	7	-	-	0.11	10.17
		<u>0.23</u>	<u>21.87</u>	<u>1.17</u>	<u>108.18</u>
<b>TOTAL</b>		<u><u>44.15</u></u>	<u><u>4,198.14</u></u>	<u><u>42.41</u></u>	<u><u>3,921.19</u></u>

|| monetary and non-monetary items in the balance sheet have been translated at closing rate of 1 GBP = Rs. 95.0882 (92.4591)

**APTIL PHARMA LTD**  
**Statement of Profit and Loss**

		Year Ended		Amt. in lacs	
		31-Mar-2016 GBP	31-Mar-2016 INR	31-Mar-2015 GBP	31-Mar-2015 INR
<b>INCOME</b>					
Revenue from operations					
Other Income	9	-	-	0.30	27.74
<b>TOTAL REVENUE</b>		<u>-</u>	<u>-</u>	<u>0.30</u>	<u>27.74</u>
<b>EXPENSES</b>					
Finance costs	10	0.89	84.63	0.58	53.63
Depreciation and amortization expense		0.07	6.66	-	-
Other expenses	11	2.30	218.70	1.79	165.50
<b>TOTAL EXPENDITURE</b>		<u>3.26</u>	<u>309.99</u>	<u>2.37</u>	<u>219.13</u>
<b>PROFIT BEFORE TAX</b>		<u>(3.26)</u>	<u>(309.99)</u>	<u>(2.07)</u>	<u>(191.39)</u>
<b>Tax expense</b>					
Current tax		-	-	-	-
Deferred tax (credit) / charge		(2.31)	(219.65)	-	-
		<u>(2.31)</u>	<u>(219.65)</u>	<u>-</u>	<u>-</u>
<b>NET PROFIT FOR THE PERIOD</b>		<u><u>(0.95)</u></u>	<u><u>(90.34)</u></u>	<u><u>(2.07)</u></u>	<u><u>(191.39)</u></u>

Notes annexed to and forming part of the Financial Statements  
**APTIL PHARMA LTD**

	As at 31-Mar-2016 GBP	As at 31-Mar-2016 INR	As at 31-Mar-2015 GBP	Amt. in lacs As at 31-Mar-2015 INR
<b>NOTE - 1 : SHARE CAPITAL</b>				
Paid-up	-	-	-	-
Paid-up	-	-	-	-
<b>NOTE - 2 : RESERVES AND SURPLUS</b>				
<b>Balance in profit and loss account</b>				
Balance as per last Balance Sheet	(8.31)	(790.18)	(6.24)	(576.94)
Add: Net profit for the current year	(0.95)	(90.34)	(2.07)	(191.39)
<b>Balance in Profit and Loss Account</b>	<b>(9.26)</b>	<b>(880.52)</b>	<b>(8.31)</b>	<b>(768.33)</b>
	<b>(9.26)</b>	<b>(880.52)</b>	<b>(8.31)</b>	<b>(768.33)</b>
<b>NOTE - 3 : BORROWINGS</b>				
<b>Short Term Borrowing</b>				
Unsecured	47.10	4,478.65	42.10	3,892.53
	<b>47.10</b>	<b>4,478.65</b>	<b>42.10</b>	<b>3,892.53</b>
<b>NOTE - 4 : DEFERRED TAX</b>				
The net deferred tax liability has been presented in balance sheet as follows:				
Deferred Tax Assets	2.31	219.65	-	-
Deferred Tax Liabilities	-	-	-	-
	<b>2.31</b>	<b>219.65</b>	<b>-</b>	<b>-</b>
<b>NOTE - 5 : OTHER LIABILITIES</b>				
<b>Current Liabilities</b>				
Interest accrued but not due on borrowings	0.46	43.74	0.58	53.63
	<b>0.46</b>	<b>43.74</b>	<b>0.58</b>	<b>53.63</b>
<b>NOTE - 7 : OTHER CURRENT ASSETS</b>				
[Unsecured and considered good, unless otherwise stated]				
Claims Receivable : Indirect tax / Insurance		-		-
Considered Good	-	-	0.11	10.17
	<b>-</b>	<b>-</b>	<b>0.11</b>	<b>10.17</b>
<b>NOTE - 8 : CASH AND CASH EQUIVALENTS</b>				
<b>Cash and cash equivalent</b>				
Balances with Banks	0.23	21.87	1.06	98.01
	<b>0.23</b>	<b>21.87</b>	<b>1.06</b>	<b>98.01</b>

APTIL PHARMA LTD	Year Ended 31-Mar-2016 GBP	Year Ended 31-Mar-2016 INR	Year Ended 31-Mar-2015 GBP	Amt. in lacs Year Ended 31-Mar-2015 INR
<b>NOTE - 9 : OTHER INCOME</b>				
Net Foreign Exchange Gain	-	-	0.30	27.74
	-	-	0.30	27.74
<b>NOTE - 10 : FINANCE COST</b>				
Interest Expense	<b>0.89</b>	<b>84.63</b>	0.58	53.63
	<b>0.89</b>	<b>84.63</b>	0.58	53.63
<b>NOTE - 11 : OTHER EXPENSES</b>				
Selling, Publicity and Medical Literature Expenses	-	-	0.02	1.85
Professional and legal fees	<b>1.23</b>	<b>116.96</b>	1.58	146.09
Registration Expenses	<b>0.94</b>	<b>89.38</b>	0.14	12.94
Net Foreign Exchange Loss	<b>0.08</b>	<b>7.61</b>	-	-
Auditors Remuneration and Expenses	<b>0.04</b>	<b>3.80</b>	0.04	3.70
General Charges	<b>0.01</b>	<b>0.95</b>	0.01	0.92
	<b>2.30</b>	<b>218.70</b>	1.79	165.50

